Vergelijking

Glepaglutide vs. Teduglutid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

geen gegevens

197922-42-2

Molecuulmassa

geen gegevens

3752.13 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Teduglutid

Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Glepaglutide	Teduglutid
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Glepaglutide

Volledige vermelding →

Teduglutid

Volledige vermelding →

Frequently asked questions

What is the difference between Glepaglutide and Teduglutid?: Glepaglutide is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Teduglutid?: The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Teduglutid in Germany and the United States?: Duitsland: Glepaglutide — Niet goedgekeurd, Teduglutid — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Teduglutid

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Glepaglutide and Teduglutid?

Glepaglutide is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Teduglutid?

The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Teduglutid in Germany and the United States?

Duitsland: Glepaglutide — Niet goedgekeurd, Teduglutid — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.